Thread by @FrontRowCME

#ESMO22 COSMIC-313 presented by @DrChoueiri Triplet therapy with cabo/nivo/ipi vs cabo/nivo for patients with advanced TN advanced intermediate or poor-risk #RCC. Primary EP: PFS; N=855

#ESMO22 #COSMIC313: Longer PFS with triplet vs doublet. mPFS NR vs 11.3 mo with benefit seen in most predefined subgroups #RCC

#ESMO22 #COSMIC313 ORR 43% vs 36% with 3% CR in both arms; mDOR not reached in either arm #RCC

#ESMO22 #COSMIC313 There were more TRAEs leading to discontinuation in the cabo/nivo/ipi arm with increased ALT, AST, and lipase most common gr3/4 AEs #RCC

Overall, at #ESMO22, #COSMIC313 showed an improvement in PFS vs doublet standard in patients with advanced IMDC intermediate- or poor-risk #RCC. There was an incremental difference in response and increased toxicity with the triplet regimen. We look forward to seeing OS data

@threadreaderapp unroll